Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H1, 2019" provides an overview of Dry (Atrophic) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

F. Hoffmann-La Roche Ltd

Astellas Pharma Inc

Biophytis SA

Vision Medicines Inc

Robert W. Snyder MD, PhD, PC

Kubota Pharmaceutical Holding

IVERIC bio Inc

Novartis AG

Leon Research SL

Apellis Pharmaceuticals Inc

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Dry (Atrophic) Macular Degeneration 38

May 08, 2019: Preclinical studies demonstrate Galimedix Therapeutics investigational compound GAL-101 shows neuroprotective effect from toxic amyloid-beta in dry AMD and glaucoma models 38

Apr 29, 2019: Catalyst Biosciences & Mosaic Biosciences present preclinical data on Pegylated CB 2782 for the treatment of Dry Age-Related Macular Degeneration 38

Apr 16, 2019: BioTime to present data from OpRegen phase I/IIa clinical study at the Association for Research in Vision and Ophthalmology Annual Meeting 38

Mar 06, 2019: Catalyst Biosciences announces poster presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 39

Feb 26, 2019: Biotime to present new data from OpRegen and vision restoration programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) 39

Clinical Trial Profile Snapshots 41

Appendix 103

Abbreviations 103

Definitions 103

Research Methodology 104

Secondary Research 104

About GlobalData 105

Contact Us 105

Source 106

List of Tables

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2019* 8

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16

Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2019* 17

Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2019* 22

Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2019* 26

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

List of Figures

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16

Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2019* 17

Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2019* 22

Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27

Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31

Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35

Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 37

GlobalData Methodology 104

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports